Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New EUS needle test could predict deadly liver bleeding

NCT ID NCT04633356

Diagnosis Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new method using an endoscope with ultrasound to measure pressure in the liver's blood vessels. It aims to see if this technique is safe and can predict complications like bleeding in 30 patients with cirrhosis from chronic hepatitis. The procedure is done during a routine upper endoscopy, making it more convenient for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EUS-portal pressure gradient measurement (PPGM) device
What this could lead to
If successful, this could provide a safer, easier way to measure portal pressure and predict complications in cirrhosis patients.
What could go wrong
This is an early-phase study with only 30 participants, so results may not apply broadly. The procedure carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2020

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Suffering from chronic hepatitis induced cirrhosis * Informed consent available Exclusion Criteria: * Medical * Child-Pugh Class C * Uncorrected platelet count \<50,000 * INR \> 1.5 (natural) * Anatomical * Previous transjugular intrahepatic or surgical portosystemic shunt * Portal vein thrombosis * Anatomic alterations of the hepatic vasculature that prevent access to the portal vein or intrahepatic portion of the hepatic veins (identified at screening and/or during the endoscopic procedure). * Previous history of spontaneous bacterial peritonitis within the previous three months * Portopulmonary hypertension * Cardiac decompensation * Endoscopically Confirmed Exclusion Criteria * Evidence of active GI bleeding (identified at screening and/or during the endoscopic procedure) * If the volume of ascites in the path of the needle prevents apposition of the gastrointestinal tract and liver. * Presence of gastric or duodenal ulcers, dieulafoy's lesion or cancers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis Portal hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese University of Hong Kong

    RECRUITING

    Hong Kong, Hong Kong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.